BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34692476)

  • 1. Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.
    Hu Y; Ren SY; Wang RY; Zeng C; Li JN; Xiao P; Wu F; Yu FL; Liu WL
    Front Oncol; 2021; 11():684070. PubMed ID: 34692476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC.
    Zhang B; Xiao Q; Xiao H; Wu J; Yang D; Tang J; Li X; Wu Z; Zhou Y; Wang W
    Front Oncol; 2022; 12():858189. PubMed ID: 35712494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study.
    Gao Y; Jiang J; Xiao D; Zhou Y; Chen Y; Yang H; Wang L; Zeng J; He B; He R; Li M; Liu Z
    Front Oncol; 2022; 12():969545. PubMed ID: 35992784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
    Rusch VW; Nicholas A; Patterson GA; Waqar SN; Toloza EM; Haura EB; Raz DJ; Reckamp KL; Merritt RE; Owen DH; Finley DJ; McNamee CJ; Blasberg JD; Garon EB; Mitchell JD; Doebele RC; Baciewicz F; Nagasaka M; Pass HI; Schulze K; Johnson A; Bunn PA; Johnson BE; Kris MG; Kwiatkowski DJ; Wistuba II; Chaft JE; Carbone DP; Lee JM
    J Thorac Cardiovasc Surg; 2023 Mar; 165(3):828-839.e5. PubMed ID: 36369159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series.
    Hu Y; Ren S; Yang L; Tong Z; Wang R; Han W; Zeng C; Li J; Xiao P; Wang L; Yu F; Liu W
    Front Pharmacol; 2022; 13():912153. PubMed ID: 35571073
    [No Abstract]   [Full Text] [Related]  

  • 10. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
    Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
    Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
    Wang H; Han Y
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
    Liu W; Zhang T; Zhang Q; Li L; Xu C
    BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Ji W; Jiang Y; Li Y; Mao W; Teng L
    Neoplasma; 2024 Feb; 71(1):88-97. PubMed ID: 38506033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.
    Shi L; Meng Q; Tong L; Li H; Dong Y; Su C; Liu Z
    Front Oncol; 2022; 12():956755. PubMed ID: 36313678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
    Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
    World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer.
    Dai J; Zhu X; Li D; Huang Y; Liu X; He W; Duan L; Zhao D; Zhu Y; Chen C; Provencio M; Ramirez RA; Antonoff MB; Wu C; Jiang G
    Transl Lung Cancer Res; 2022 Feb; 11(2):188-200. PubMed ID: 35280313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
    Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
    J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
    Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
    Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.